Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities
Conclusion:
Cancer patients carry a high burden of CVD-related comorbidities before the application of VEGF antagonists. HTN is the most prevalent comorbid condition, and cancer patients with HTN constitute substantial cardiovascular risks and a higher co-prevalence of other CVDs.
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Epidemiology Source Type: research
More News: Atrial Fibrillation | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Colorectal Cancer | Coronary Heart Disease | Epidemiology | Heart | Heart Failure | Hepatocellular Carcinoma | Hypertension | Kidney Cancer | Liver Cancer | Lung Cancer | Renal Cell Carcinoma | Study | Thyroid | Thyroid Cancer